The tests are designed to detect genetic variations including SNPs, insertion-deletions, copy number variations, and variations in segmental duplications.
The test covers 27 genes in which variants are known to contribute to the effectiveness or safety of more than 360 medications for 30 conditions.
The test is the first whole-genome-based cancer test to receive approval from New York State's Department of Health.
With the approval, MDxHealth can now offer its liquid biopsy molecular diagnostic assay in all 50 US states.
NYSDOH's move away from susceptibility testing for isolates that are known to be pan-susceptible will be coordinated with similar international efforts.
The tests can detect several species of Borrelia burgdorferi, the tick-borne parasite primarily responsible for all Lyme disease cases in the US.
Despite the astronomical costs, it may prove challenging to reverse course and discontinue Zika testing according to a commentary article accompanying a NEJM study.
The approvals allow the company to offer its PCR-based expression profile cancer risk tests in the state.
With the accreditation, the La Jolla, California-based molecular dermatology firm can provide its services in all 50 states and the District of Columbia.
The genetic testing firm can now offer its Prelude noninvasive prenatal test to residents in New York State.